111
Participants
Start Date
April 30, 2015
Primary Completion Date
December 31, 2015
Study Completion Date
January 31, 2016
LDV/SOF
90/400 mg FDC tablet administered orally once daily
RBV
Tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
Calgary
Edmonton
Edmonton
Vancouver
Vancouver
Vancouver
Brampton
London
Ottawa
Toronto
Toronto
Vaughan
Montreal
Montreal
Québec
Lead Sponsor
Gilead Sciences
INDUSTRY